ArticleThe British journal of ophthalmology2021
Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser.
Article in The British journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Risk factors of retinal vein occlusion in East Asia: a meta-analysis.Frontiers in ophthalmology · 2025Pooled it
- Long term efficacy and safety profile of dexamethasone intravitreal implant in retinal vein occlusions: a systematic review.Frontiers in medicine · 2024Pooled it
- Anti-Vascular Endothelial Growth Factor Combined with Dexamethasone Implant Therapy for Macular Edema: A Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- RVO-ME: A Dual-Task OCT Dataset for Segmentation and Detection of Macular Lesions in Retinal Vein Occlusion.Scientific data · 2026Article
- Correlation of retinal thickness, macular volume, and their fluctuation with visual outcomes in patients with macular edema due to retinal vein occlusion.International journal of retina and vitreous · 2025Article
- Three-year outcomes of cystotomy for cystoid macular edema secondary to retinal vein occlusion.PloS one · 2025Observational
- Global trends in retinal vein occlusion studies from 2004 to 2023: a bibliometric analysis.International journal of ophthalmology · 2025Article
- Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry.Scientific reports · 2024Observational
- A Datasheet for the INSIGHT University Hospitals Birmingham Retinal Vein Occlusion Data Set.Ophthalmology science · 2023Article
- Exploring regression to the mean in visual acuities by investigating measurements at two consecutive time points in untreated fellow eyes.Eye (London, England) · 2023Article
- [Retinal vein occlusion : Intravitreal pharmacotherapies and treatment strategies for the management of macular edema].Die Ophthalmologie · 2022Review
- Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology.Scientific reports · 2022Article
- Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment.Scientific reports · 2022Article
- Dexamethasone Intravitreal Implant for the Treatment of Macular Edema and Uveitis: A Comprehensive Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
- Real-world outcomes of anti-vascular endothelial growth factor therapy for retinal vascular vein occlusion in Tibet, China.International journal of ophthalmology · 2022Article
- Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes.The British journal of ophthalmology · 2021Article
- Treatment outcomes for maculopathy secondary to retinal vein occlusion in Afghanistan.Oman journal of ophthalmologyArticle
- Treatment Patterns and Clinical Outcomes for Branch Retinal Vein Occlusion: An 8-Year Experience at a Tertiary Eye Center.Journal of vitreoretinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
BACKGROUND/
aimsClinical trials suggest anti-vascular endothelial growth factor is more effective than intravitreal dexamethasone as treatment for macular oedema secondary to branch retinal vein occlusion. This study asks if 'real world' data from a larger and more diverse population, followed for a longer period, also support this conclusion.
methodsData collected to support routine care at 27 NHS (National Health Service) Trusts between February 2002 and September 2017 contained 5661 treatment-naive patients with a single mode of treatment for macular oedema secondary to branch retinal vein occlusion and no history of cataract surgery either during or recently preceding the treatment. Number of treatment visits and change in visual acuity from baseline was plotted for three treatment groups (anti-vascular endothelial growth factor (anti-VEGF), intravitreal dexamethasone, macular laser) for up to 3 years.
resultsMean baseline visual acuity was 57.1/53.1/62.3 letters in the anti-VEGF/dexamethasone/macular laser groups, respectively. This changed to 66.72 (+9.6)/57.6 (+4.5)/63.2 (+0.9) at 12 months. Adequate numbers allowed analysis at 18 months for all groups (66.6 (+9.5)/56.1 (+3.0)/60.8 (-1.5)) and for anti-VEGF at 36 months (68.0, +10.9) Mean number of treatments were 5.1/1.5/1.2 at 12 months, 5.9/1.7/1.2 at 18 months for all three groups and 10.3 at 36 months for anti-VEGF.
conclusionsVisual acuity improvements were higher and more sustained with anti-VEGF. Higher treatment burden occurred with anti-VEGF but this reduced over 36 months. Patients with better vision at baseline than those in the clinical trials maintained high levels of vision with both anti-VEGF and dexamethasone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.